Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
- PMID: 20667129
- PMCID: PMC2915985
- DOI: 10.1186/1471-2407-10-396
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
Abstract
Background: HER2 gene copy status, and concomitant administration of trastuzumab (Herceptin), remains one of the best examples of targeted cancer therapy based on understanding the genomic etiology of disease. However, newly diagnosed breast cancer cases with equivocal HER2 results present a challenge for the oncologist who must make treatment decisions despite the patient's unresolved HER2 status. In some cases both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are reported as equivocal, whereas in other cases IHC results and FISH are discordant for positive versus negative results. The recent validation of array-based, molecular karyotyping for clinical oncology testing provides an alternative method for determination of HER2 gene copy number status in cases remaining unresolved by traditional methods.
Methods: In the current study, DNA extracted from 20 formalin fixed paraffin embedded (FFPE) tissue samples from newly diagnosed cases of invasive ductal carcinoma referred to our laboratory with unresolved HER2 status, were analyzed using a clinically validated genomic array containing 127 probes covering the HER2 amplicon, the pericentromeric regions, and both chromosome 17 arms.
Results: Array-based comparative genomic hybridization (array CGH) analysis of chromosome 17 resolved HER2 gene status in [20/20] (100%) of cases and revealed additional chromosome 17 copy number changes in [18/20] (90%) of cases. Array CGH analysis also revealed two false positives and one false negative by FISH due to "ratio skewing" caused by chromosomal gains and losses in the centromeric region. All cases with complex rearrangements of chromosome 17 showed genome-wide chromosomal instability.
Conclusions: These results illustrate the analytical power of array-based genomic analysis as a clinical laboratory technique for resolution of HER2 status in breast cancer cases with equivocal results. The frequency of complex chromosome 17 abnormalities in these cases suggests that the two probe FISH interphase analysis is inadequate and results interpreted using the HER2/CEP17 ratio should be reported "with caution" when the presence of centromeric amplification or monosomy is suspected by FISH signal gains or losses. The presence of these pericentromeric copy number changes may result in artificial skewing of the HER2/CEP17 ratio towards false negative or false positive results in breast cancer with chromosome 17 complexity. Full genomic analysis should be considered in all cases with complex chromosome 17 aneusomy as these cases are likely to have genome-wide instability, amplifications, and a poor prognosis.
Figures
Similar articles
-
Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.Tumour Biol. 2016 Jul;37(7):8665-72. doi: 10.1007/s13277-015-4657-7. Epub 2016 Jan 6. Tumour Biol. 2016. PMID: 26738861
-
[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Zhonghua Bing Li Xue Za Zhi. 2006. PMID: 17134563 Chinese.
-
Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.Cancer Genet Cytogenet. 2004 Dec;155(2):108-18. doi: 10.1016/j.cancergencyto.2004.02.023. Cancer Genet Cytogenet. 2004. PMID: 15571796
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
-
Double-Equivocal HER2 Invasive Breast Carcinomas: Institutional Experience and Review of Literature.Arch Pathol Lab Med. 2018 Dec;142(12):1511-1516. doi: 10.5858/arpa.2017-0265-RA. Epub 2018 Mar 29. Arch Pathol Lab Med. 2018. PMID: 29595316 Review.
Cited by
-
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.Breast J. 2023 Nov 30;2023:6621409. doi: 10.1155/2023/6621409. eCollection 2023. Breast J. 2023. PMID: 38075551 Free PMC article.
-
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry.Cancer Cell Int. 2022 Nov 15;22(1):350. doi: 10.1186/s12935-022-02761-1. Cancer Cell Int. 2022. PMID: 36376842 Free PMC article.
-
Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma.Oncol Lett. 2021 Feb;21(2):142. doi: 10.3892/ol.2020.12403. Epub 2020 Dec 21. Oncol Lett. 2021. PMID: 33552261 Free PMC article.
-
Matrix Metalloproteinase 13 from Satellite Cells is Required for Efficient Muscle Growth and Regeneration.Cell Physiol Biochem. 2020 Apr 11;54(3):333-353. doi: 10.33594/000000223. Cell Physiol Biochem. 2020. PMID: 32275813 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
References
-
- Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145. doi: 10.1200/JCO.2006.09.2775. - DOI - PubMed
-
- Marchio C, Lambros MB, Gugliotta P, Di Cantogno LVD, Botta C, Pasini B, Tan DSP, Mackay A, Fenwick K, Tamber N, Bussolati G, Asworth A, Reis-Fiho JS, Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16–24. doi: 10.1002/path.2574. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous